10-Q quarterly report · filed Nov 5, 2026

Janux Therapeutics, Inc. (JANX) Q3 2026 10-Q Quarterly Report

Short answer

Janux Therapeutics, Inc. (JANX) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $9M (down 7.1% year over year) with net income of −$22M.

Q3 2026 key financials · XBRL

Revenue
$9M
−7.1% YoY · −9.5% QoQ
Net income
−$22M
+11.3% YoY · +1.8% QoQ
Operating margin
-336.5%
EPS (diluted)
−$0.34
+12.8% YoY · +2.9% QoQ

Source: XBRL data from the Janux Therapeutics, Inc. (JANX) Q3 2026 10-Q on SEC EDGAR. USD.

Janux Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Collaboration revenue $9.3M, down $0.7M YoY, BMS revenue offsetting lower Merck revenue
  • Net loss $21.6M vs $24.3M YoY, operating loss $31.3M vs $35.3M
  • JANX007 highest R&D spend at $6.7M, up $0.5M; JANX013 lowest at $1.0M, down $2.6M
  • Cash, restricted cash and short-term investments $946.5M; operating cash use $25.0M vs $53.7M YoY
  • Existing liquidity expected to fund operations and capital expenditures through at least the next 12 months; clinical spending headwind

Risk Factors

  • Clinical discontinuation of JANX008 in April 2026 after Phase 1a activity proved insufficient versus other pipeline programs
  • Regulatory risk: U.S. FDA staffing cuts may delay IND reviews, guidance and future approvals
  • Manufacturing concentration: BDS for each product candidate expected to rely on single-source suppliers
  • Liquidity risk: $945.7 million in cash, equivalents and short-term investments funds operations for at least 12 months
  • Competitive risk: larger biopharmaceutical companies may develop safer, more effective or cheaper immunotherapies faster

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Janux Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.